Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus

Sari A. Jouihan, Kristen L. Zuloaga, Wenri Zhang, Robert Shangraw, Stephanie Krasnow, Daniel Marks, Nabil Alkayed

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Hyperglycemia worsens stroke, yet rigorous glycemic control does not improve neurologic outcome. An alternative is to target downstream molecular mediator(s) triggered by hyperglycemia but independent of prevailing glycemia. Soluble epoxide hydrolase (sEH) is a potential mediator of injury via its metabolism of neuroprotective epoxyeicosatrienoic acids (EETs). We tested whether hyperglycemia exacerbates cerebral injury by upregulating sEH and decreasing brain EET levels. Type 1 diabetes mellitus was modeled by streptozotocin (STZ; 50 mg/kg per day intraperitoneally, 5 days) in male mice. At 4 weeks, STZ-treated and control mice underwent 45-minute middle cerebral artery occlusion (MCAO) with or without sEH blockade by trans-4-4-(3-adamantan- 1-yl-ureido)-cyclohexyloxy-benzoic acid (t-AUCB; 1 mg/kg intraperitoneally daily for 6 days before MCAO). The STZ-treated mice had increased sEH mRNA expression in cerebral vessels and decreased EET concentrations in brain. There was no difference in cortical perfusion between groups. The STZ-treated mice sustained larger brain infarct than controls. Pretreatment with t-AUCB eliminated the difference in infarct size and EETs concentration between STZ-treated mice and controls, without altering glycemia. We conclude that type 1 diabetes mellitus upregulates sEH mRNA and decreases concentrations of neuroprotective EETs within the brain, leading to worse stroke outcome. The data indicate that sEH antagonism may be beneficial in the setting of hyperglycemic stroke.

Original languageEnglish (US)
Pages (from-to)1650-1656
Number of pages7
JournalJournal of Cerebral Blood Flow and Metabolism
Volume33
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Epoxide Hydrolases
Streptozocin
Type 1 Diabetes Mellitus
Stroke
Hyperglycemia
Middle Cerebral Artery Infarction
Brain
Messenger RNA
Benzoic Acid
Wounds and Injuries
Nervous System
Up-Regulation
Perfusion
Acids

Keywords

  • diabetes mellitus
  • EPHX2
  • hyperglycemia
  • streptozotocin
  • t-AUCB

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Neurology

Cite this

Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus. / Jouihan, Sari A.; Zuloaga, Kristen L.; Zhang, Wenri; Shangraw, Robert; Krasnow, Stephanie; Marks, Daniel; Alkayed, Nabil.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 33, No. 10, 10.2013, p. 1650-1656.

Research output: Contribution to journalArticle

@article{d271c7cb7cd348fa83d97bcab510a594,
title = "Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus",
abstract = "Hyperglycemia worsens stroke, yet rigorous glycemic control does not improve neurologic outcome. An alternative is to target downstream molecular mediator(s) triggered by hyperglycemia but independent of prevailing glycemia. Soluble epoxide hydrolase (sEH) is a potential mediator of injury via its metabolism of neuroprotective epoxyeicosatrienoic acids (EETs). We tested whether hyperglycemia exacerbates cerebral injury by upregulating sEH and decreasing brain EET levels. Type 1 diabetes mellitus was modeled by streptozotocin (STZ; 50 mg/kg per day intraperitoneally, 5 days) in male mice. At 4 weeks, STZ-treated and control mice underwent 45-minute middle cerebral artery occlusion (MCAO) with or without sEH blockade by trans-4-4-(3-adamantan- 1-yl-ureido)-cyclohexyloxy-benzoic acid (t-AUCB; 1 mg/kg intraperitoneally daily for 6 days before MCAO). The STZ-treated mice had increased sEH mRNA expression in cerebral vessels and decreased EET concentrations in brain. There was no difference in cortical perfusion between groups. The STZ-treated mice sustained larger brain infarct than controls. Pretreatment with t-AUCB eliminated the difference in infarct size and EETs concentration between STZ-treated mice and controls, without altering glycemia. We conclude that type 1 diabetes mellitus upregulates sEH mRNA and decreases concentrations of neuroprotective EETs within the brain, leading to worse stroke outcome. The data indicate that sEH antagonism may be beneficial in the setting of hyperglycemic stroke.",
keywords = "diabetes mellitus, EPHX2, hyperglycemia, streptozotocin, t-AUCB",
author = "Jouihan, {Sari A.} and Zuloaga, {Kristen L.} and Wenri Zhang and Robert Shangraw and Stephanie Krasnow and Daniel Marks and Nabil Alkayed",
year = "2013",
month = "10",
doi = "10.1038/jcbfm.2013.130",
language = "English (US)",
volume = "33",
pages = "1650--1656",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus

AU - Jouihan, Sari A.

AU - Zuloaga, Kristen L.

AU - Zhang, Wenri

AU - Shangraw, Robert

AU - Krasnow, Stephanie

AU - Marks, Daniel

AU - Alkayed, Nabil

PY - 2013/10

Y1 - 2013/10

N2 - Hyperglycemia worsens stroke, yet rigorous glycemic control does not improve neurologic outcome. An alternative is to target downstream molecular mediator(s) triggered by hyperglycemia but independent of prevailing glycemia. Soluble epoxide hydrolase (sEH) is a potential mediator of injury via its metabolism of neuroprotective epoxyeicosatrienoic acids (EETs). We tested whether hyperglycemia exacerbates cerebral injury by upregulating sEH and decreasing brain EET levels. Type 1 diabetes mellitus was modeled by streptozotocin (STZ; 50 mg/kg per day intraperitoneally, 5 days) in male mice. At 4 weeks, STZ-treated and control mice underwent 45-minute middle cerebral artery occlusion (MCAO) with or without sEH blockade by trans-4-4-(3-adamantan- 1-yl-ureido)-cyclohexyloxy-benzoic acid (t-AUCB; 1 mg/kg intraperitoneally daily for 6 days before MCAO). The STZ-treated mice had increased sEH mRNA expression in cerebral vessels and decreased EET concentrations in brain. There was no difference in cortical perfusion between groups. The STZ-treated mice sustained larger brain infarct than controls. Pretreatment with t-AUCB eliminated the difference in infarct size and EETs concentration between STZ-treated mice and controls, without altering glycemia. We conclude that type 1 diabetes mellitus upregulates sEH mRNA and decreases concentrations of neuroprotective EETs within the brain, leading to worse stroke outcome. The data indicate that sEH antagonism may be beneficial in the setting of hyperglycemic stroke.

AB - Hyperglycemia worsens stroke, yet rigorous glycemic control does not improve neurologic outcome. An alternative is to target downstream molecular mediator(s) triggered by hyperglycemia but independent of prevailing glycemia. Soluble epoxide hydrolase (sEH) is a potential mediator of injury via its metabolism of neuroprotective epoxyeicosatrienoic acids (EETs). We tested whether hyperglycemia exacerbates cerebral injury by upregulating sEH and decreasing brain EET levels. Type 1 diabetes mellitus was modeled by streptozotocin (STZ; 50 mg/kg per day intraperitoneally, 5 days) in male mice. At 4 weeks, STZ-treated and control mice underwent 45-minute middle cerebral artery occlusion (MCAO) with or without sEH blockade by trans-4-4-(3-adamantan- 1-yl-ureido)-cyclohexyloxy-benzoic acid (t-AUCB; 1 mg/kg intraperitoneally daily for 6 days before MCAO). The STZ-treated mice had increased sEH mRNA expression in cerebral vessels and decreased EET concentrations in brain. There was no difference in cortical perfusion between groups. The STZ-treated mice sustained larger brain infarct than controls. Pretreatment with t-AUCB eliminated the difference in infarct size and EETs concentration between STZ-treated mice and controls, without altering glycemia. We conclude that type 1 diabetes mellitus upregulates sEH mRNA and decreases concentrations of neuroprotective EETs within the brain, leading to worse stroke outcome. The data indicate that sEH antagonism may be beneficial in the setting of hyperglycemic stroke.

KW - diabetes mellitus

KW - EPHX2

KW - hyperglycemia

KW - streptozotocin

KW - t-AUCB

UR - http://www.scopus.com/inward/record.url?scp=84885018925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885018925&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2013.130

DO - 10.1038/jcbfm.2013.130

M3 - Article

C2 - 23899929

AN - SCOPUS:84885018925

VL - 33

SP - 1650

EP - 1656

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 10

ER -